Neumora Reports Positive Preclinical Results for NMRA-215

Neumora Therapeutics, Inc. ( (NMRA) ) has provided an update.

On October 27, 2025, Neumora Therapeutics announced positive preclinical results for NMRA-215, an oral NLRP3 inhibitor, in diet-induced obesity mouse studies. The studies showed significant weight loss, with NMRA-215 achieving up to 19% weight reduction as a monotherapy and 26% when combined with semaglutide. These findings suggest NMRA-215’s potential as a next-generation treatment for obesity, both alone and in combination with GLP-1 agonists, and Neumora plans to initiate Phase 1 clinical trials in early 2026.

The most recent analyst rating on (NMRA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Neumora Therapeutics, Inc. stock, see the NMRA Stock Forecast page.

Spark’s Take on NMRA Stock

According to Spark, TipRanks’ AI Analyst, NMRA is a Underperform.

Neumora Therapeutics, Inc. is significantly challenged by its financial position, with ongoing losses and no revenue. Technical analysis indicates bearish momentum, and valuation is difficult in the absence of earnings. While promising pipeline advancements and a strong cash position offer some optimism, the overall outlook is hindered by recent clinical setbacks and financial instability.

To see Spark’s full report on NMRA stock, click here.

More about Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on redefining neuroscience drug development. The company aims to address significant medical challenges by developing treatments for brain diseases, with a therapeutic pipeline that includes seven programs targeting novel mechanisms for various prevalent and underserved conditions.

Average Trading Volume: 986,847

Technical Sentiment Signal: Hold

Current Market Cap: $425.9M

Learn more about NMRA stock on TipRanks’ Stock Analysis page.